NFA
LPCN icon

Nationwide Fund Advisors’s Lipocine LPCN Stock Holding History

Nationwide Fund Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-619
Closed -$41K – 3234
2017
Q1 		$41K Hold
619
– – ﹤0.01% 3012
2016
Q4 		$39K Hold
619
– – ﹤0.01% 3033
2016
Q3 		$47K Hold
619
– – ﹤0.01% 3058
2016
Q2 		$32K Buy
+619
New +$95.9K ﹤0.01% 3120

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Nationwide Fund Advisors's LPCN Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Lipocine (LPCN) in Q2 2017, closing a stake of 619 shares — an estimated $41K sold.

Nationwide Fund Advisors first reported a position in LPCN in Q2 2016 and held it in 4 quarters. The position peaked at $47K in Q3 2016. 42 funds tracked by Wall St. Rank hold LPCN as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Lipocine position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 619 Lipocine shares in Q2 2017, an estimated $41K.
  • Nationwide Fund Advisors first reported a position in Lipocine in Q2 2016 and held it in 4 quarters.
  • Nationwide Fund Advisors's Lipocine position peaked at $47K in Q3 2016.
  • 42 funds tracked by Wall St. Rank held Lipocine as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.